GLP-1 Warning Over Link to Fatal Events; DOJ Sues Med School; Genes and Longevity
(MedPage Today) — Note that some links may require registration or subscription.
The United Kingdom’s Medicines and Healthcare Products Regulatory Agency strengthened its warnings on GLP-1 receptor agonists and dual GLP-1/GIP agonists to include…
Amputation Risk in Diabetes Drops With GLP-1 Drugs, Study Suggests
(MedPage Today) — GLP-1 receptor agonist use was tied to a lower risk of recurrent major adverse limb events (MALEs) in people with diabetes compared with another drug class, a retrospective Taiwanese study showed.
Among 17,288 patients, new…
There Are Many Types of Obesity, Says This GLP-1 Expert
A renowned physician-scientist says treatment is not one-size-fits-all.
GLP-1 Receptor Agonists Tied to Lower Revision Rate After Functional Endoscopic Sinus Surgery
THURSDAY, Jan. 29, 2026 — Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with reduced postoperative revision following functional endoscopic sinus surgery (FESS) for up to five years among patients with chronic…
‘Night Owls’ and Heart Risks; AI Grades Med School Exams; GLP-1 Drug Patients Sue
(MedPage Today) — Note that some links may require registration or subscription.
“Night owls” may be at higher risk of cardiovascular disease, but it mostly comes down to their overall health behaviors, according to a U.K. Biobank cohort study…
Dual GIP/GLP-1 Drug Linked to Reduced Diabetic Retinopathy Incidence
(MedPage Today) — Use of tirzepatide (Mounjaro, Zepbound) was tied to a reduced incidence of new or progressive diabetic retinopathy and fewer complications in patients with diabetes and overweight/obesity, a retrospective study suggested.
In…
Study raises red flags over long-term effectiveness of popular weight loss drugs like Ozempic
Ozempic, Mounjaro, and Zepbound can drive impressive weight loss, but stopping them is often followed by rapid weight regain. Researchers found that people regain weight faster after quitting these drugs than after diet and exercise alone. Improvements in heart health and diabetes risk also tend to reverse within a few years. The results suggest long-term success may require more than medication alone.
Tirzepatide Safety Warning; Nurse Charged Over Fake GLP-1s; Revised Afrezza Dosing
(MedPage Today) — Tirzepatide (Mounjaro, Zepbound) users should never share KwikPens due to risk for transmission of blood-borne pathogens, the FDA warned in an updated label.
GLP-1 medications for weight loss accounted for more than 7% of all…
Roche’s 22% Weight Loss Benefit Seals GLP-1’s Phase III Plans, Boosts Zealand Combo
Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.
Menopause Hormone Therapy May Boost GLP-1 Drug Benefits
(MedPage Today) — Postmenopausal women on the GLP-1 medication tirzepatide (Zepbound) for obesity lost more weight if they were also using menopause hormone therapy, a retrospective cohort study indicated.
Among 120 women with overweight or obesity…